

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor of the subject matter (an original, first and joint inventor) which is claimed and for which a utility patent is sought on the invention entitled:

INHIBITION OF MAL1

the specification of which:

- ☐ was filed on _____ as United States non-provisional application U.S.S.N. ,
bearing Attorney Docket No. _____
- ☒ is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

- ☐ I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

[illegible]

☒ I hereby claim the benefit under Title 35, United States Code, § 119(e) or §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

Application No. <i>(U.S.S.N.)</i>	Filing Date <i>(dd/mm/yy)</i>	Status <i>(Patented, Pending, Abandoned, Expired)</i>
60/183,106	17 February 2000	Pending

PCT International Applications designating the United States:

PCT International Application No.	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
Kevin N. Ainsworth	39,586	Christina V. Karnakis	45,899
Ingrid A. Beattie	42,306	Robert V. Klauzinski	42,742
William Belanger	40,509	Kristin E. Konzak	44,848
Naomi Biswas	38,384	Cynthia Kozakiewicz	42,764
Duane Blake	47,279	Barry J. Marenberg	40,715
Yong Choi	43,324	William A. Marino	44,219
David F. Crosby	36,400	A. Jason Mirabito	28,161
Brett N. Dorny	35,860	Michel Morency	Limited Recognition
Marianne Downing	42,870	Bradley Olson	40,750
Ivor R. Elrifi	39,529	Carol H. Peters	45,010
Heidi A. Erlacher	45,409	David W. Poirier	43,007
Christina Gadiano	37,628	Michael Renaud	44,299
Richard Gervase	P-46,725	Brian Rosenbloom	41,276
John A. Harre	37,345	Robert J. Sayre	42,124
Brian P. Hopkins	42,669	Thomas M. Sullivan	39,392
Shane Hunter	41,858	Janine M. Susan	46,119
David E. Johnson	41,874	Howard Susser	33,556
Kris Kalidindi	41,461	Shelby J. Walker	45,192

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicant's attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

Address all telephone calls to **Ingrid A. Beattie** at telephone number 617/348-1838.
Address all correspondence to:

Ingrid A. Beattie
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

Inventor's Signature

Date

Full Name of Inventor: Gokhan S. Hotamisligil

Citizenship: Turkey

Residence: 10 Rogers Street, #306, Cambridge, MA 02142

Post Office Address: 10 Rogers Street, #306, Cambridge, MA 02142

TRADOCS:1439666.1(%%Q01!.DOC)

[illegible]

9

Level - 2
Version 1.1

Express Mail Label No.: EK611846760US

Date of Deposit: February 16, 2001

Attorney Docket No. 21509-044

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Gokhan S. Hotamisligil
ASSIGNEE: President and Fellows of Harvard College
SERIAL NUMBER: To Be Assigned EXAMINER: To Be Assigned
FILING DATE: February 16, 2001 ART UNIT: To Be Assigned
FOR: INHIBITION OF MAL1

February 16, 2001
Boston, Massachusetts

Box New Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

**STATEMENT IN SUPPORT OF COMPUTER READABLE
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)**

Sir:

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same.

Respectfully submitted,


Ivor R. Elrifi, Reg. No.: 39,529
Ingrid A. Beattie, Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRADOCS:1439843.1(%%ZN01!.DOC)

SEQUENCE LISTING

<110> Hotamisligil, Gokhan S.

<120> INHIBITION OF MAL1

<130> 21509-044

<140> Not Yet Assigned

<141> 2001-02-16

<150> 60/183,106

<151> 2000-02-17

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 135

<212> PRT

<213> Mus musculus

<400> 1

Met	Ala	Ser	Leu	Lys	Asp	Leu	Glu	Gly	Lys	Trp	Arg	Leu	Met	Glu	Ser
1				5					10					15	

His	Gly	Phe	Glu	Glu	Tyr	Met	Lys	Glu	Leu	Gly	Val	Gly	Leu	Ala	Leu
			20					25					30		

Arg	Lys	Met	Ala	Ala	Met	Ala	Lys	Pro	Asp	Cys	Ile	Ile	Thr	Cys	Asp
		35					40					45			

Gly	Asn	Asn	Ile	Thr	Val	Lys	Thr	Glu	Ser	Thr	Val	Lys	Thr	Thr	Val
	50					55						60			

Phe	Ser	Cys	Asn	Leu	Gly	Glu	Lys	Phe	Asp	Glu	Thr	Thr	Ala	Asp	Gly
65					70					75					80

Arg	Lys	Thr	Glu	Thr	Val	Cys	Thr	Phe	Gln	Asp	Gly	Ala	Leu	Val	Gln
					85				90					95	

His	Gln	Gln	Trp	Asp	Gly	Lys	Glu	Ser	Thr	Ile	Thr	Arg	Lys	Leu	Lys
					100				105				110		

Asp	Gly	Lys	Met	Ile	Val	Glu	Cys	Val	Met	Asn	Asn	Ala	Thr	Cys	Thr
							115				120			125	

Arg Val Tyr Glu Lys Val Gln
 130 135

<210> 2
 <211> 1279
 <212> DNA
 <213> Mus musculus

<400> 2
 aatgggagca acatgctagc tatgcaggctc ggtgagtgag tgagtgagtg acaagaggct 60
 ggccagtggg atgataagga atgaatcctt gcttatcatt gtacaaatta cgtcattttc 120
 catacccaca ggagtaggac tggctcttag gaagatggct gccatggcca agccagactg 180
 tatcattacg tgtgatggca acaacatcac ggtcaaaacc gagagcacag tgaagacgac 240
 tgtgttctct tgtaacctgg gagagaagtt tgatgaaacg acagctgatg gcagaaaaaac 300
 tgaggtcagc tacaacatac tgtgaagcga cagaagcttc tagatttaca gattaaattg 360
 cattaacaat gtctgtactt actgccaagg gctgactgaa aaaactactt tatggagttg 420
 acttttgata aattagtaaa agtcccagga ctaagaaatg aagacatctt atgagtttct 480
 agatcgaaaa gcacatagtt gtattgtgaa caaaatcagt atgatggggt ggagttcaga 540
 gagggaaaagg cgaagacttg ttggagtggt gtgggtcctg ggggttcctt cactttggaa 600
 gatgatgaac taactaccct gtatttttgc agacggctctg caccttccaa gacggtgccc 660
 tggtcagca ccagcaatgg gacgggaagg agagcacgat aacaagaaaa ctgaaggatg 720
 ggaagatgat cgtgggtgagc atcaaagcac tggcaccatg ctgggattgg gcctgcagcc 780
 acagttgtca taaccacttc gggtcattgg ttctttaaca agagaaggaa acttaggagg 840
 acaatactga aaataacaag ttagaaacga gagtcctcat tgctgaggca gcccttgagg 900
 ggacggagaa gtgatgggat cccaggatgt ggctgcagca gagcctgaga gctggcaggc 960
 caccgagcag cctctctctg gtacattgat ttaagtaagg gatatttgcc aaaacacatg 1020
 aataatttag agatcatatc cagtgcctta gtctgcaggg cagcaaatat acatataaac 1080
 aaaacagcag ctctaggtct tcttgagttt gaatcctgag atgtggtttt tctgttaggt 1140
 tggttacaag cgtttatagg attctgcccc caacacatgc tctgaaatgt acagttggcc 1200
 tgagactcta tctttcttct cctaggagtg tgtcatgaac aatgccacct gcactcgggt 1260
 ctatgagaag gtgcaatga 1279

<210> 3
 <211> 135
 <212> PRT
 <213> Homo sapiens

<400> 3
 Met Ala Thr Val Gln Gln Leu Glu Gly Arg Trp Arg Leu Val Asp Ser
 1 5 10 15
 Lys Gly Phe Asp Glu Tyr Met Lys Glu Leu Gly Val Gly Ile Ala Leu
 20 25 30
 Arg Lys Met Gly Ala Met Ala Lys Pro Asp Cys Ile Ile Thr Cys Asp
 35 40 45

Gly Lys Asn Leu Thr Ile Lys Thr Glu Ser Thr Leu Lys Thr Thr Gln
 50 55 60

Phe Ser Cys Thr Leu Gly Glu Lys Phe Glu Glu Thr Thr Ala Asp Gly
 65 70 75 80

Arg Lys Thr Gln Thr Val Cys Asn Phe Thr Asp Gly Ala Leu Val Gln
 85 90 95

His Gln Glu Trp Asp Gly Lys Glu Ser Thr Ile Thr Arg Lys Leu Lys
 100 105 110

Asp Gly Lys Leu Val Val Glu Cys Val Met Asn Asn Val Thr Cys Thr
 115 120 125

Arg Ile Tyr Glu Lys Val Glu
 130 135

<210> 4

<211> 662

<212> DNA

<213> Homo sapiens

<400> 4

accgccgacg cagacccctc tctgcacgcc agcccgcccg caccaccat ggccacagtt 60
 cagcagctgg aaggaagatg gcgcctggtg gacagcaaag gctttgatga atacatgaag 120
 gagctaggag tgggaatagc tttgcgaaaa atgggcgcaa tggccaagcc agattgtatc 180
 atcacttgtg atggtaaaaa cctcaccata aaaactgaga gcactttgaa aacaacacag 240
 ttttcttgta ccctggggaga gaagtttgaa gaaaccacag ctgatggcag aaaaactcag 300
 actgtctgca actttacaga tgggtgcattg gttcagcatc aggagtggga tgggaaggaa 360
 agcacaataa caagaaaatt gaaagatggg aaattagtgg tggagtgtgt catgaacaat 420
 gtcacctgta ctcgatcta tgaaaaagta gaataaaaat tccatcatca ctttggacag 480
 gagttaatta agagaatgac caagctcagt tcaatgagca aatctccata ctgtttcttt 540
 cttttttttt tcattactgt gttcaattat ctttatcata aacattttac atgcagctat 600
 ttcaaagtgt gttggattaa ttaggatcat ccctttggtt aataaataaa tgtgtttgtg 660
 ct 662